Project Grant R01CA294792
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $742K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The federal Project Grant award of $202,982.00 was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Cold Spring Harbor Laboratory to conduct research aimed at "Understanding and Targeting Senescence in Clonal Hematopoiesis". The research project seeks to identify inflammatory mediators and cell-autonomous pathways in clonal hematopoiesis (CH) that may serve as potential therapeutic targets to restore oligoclonal hematopoiesis and address the adverse...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,771 to The Washington University to investigate the impact of clonal hematopoiesis on solid tumor development and response to radiation therapy. Specifically, the project aims to quantify the effect of TET2-mutant hematopoietic cells on lung tumor growth and treatment, as well as identify the spectrum of clonal hematopoiesis-mutant immune cells that infiltrate the tumor...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $388,749 to The Washington University in Missouri to conduct research focused on understanding the impact of clonal hematopoiesis on the aging human bone marrow. The goal is to investigate how these somatic mutations that can drive leukemia exist and interact within the bone marrow niche in cancer-free adults, which may yield insights into how these pre-malignant states...
- This federal Project Grant award of $225,101 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the mechanisms underlying the increased risk of hematological malignancies in sickle cell disease patients. The key objectives of this 2-year project are to: 1) Perform experiments to understand how increased oxidative stress and DNA damage in hematopoietic stem and progenitor cells lead to the development of clonal...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This Project Grant award of $125,532.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the disruption of the clonal architecture of human hematopoietic stem cells driven by high-effect somatic and germline genetic variants, and identify the resulting phenotypic changes that lead to impaired stem cell function and increased disease risk with aging. The research will utilize a mitochondrial lineage tracing...
- This federal Project Grant award of $464,212.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize the biological mechanisms underlying the pleiotropic effects of genetic variation at the TERT/CLPTM1L locus on cancer susceptibility and aging-related traits. The University of Chicago, the awardee, will integrate large-scale genetic association data, multi-omic quantitative trait loci (QTLs) in stem/differentiating cells, and...
- This federal Project Grant award of $676,550 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to understand the impact of socioeconomic status (SES) and adversity on hematopoietic cell transplant (HCT) outcomes in pediatric patients with high-risk hematological malignancies. The primary goals are to: 1) quantify the association between donor and recipient SES with pediatric HCT outcomes, and 2) evaluate how donor and recipient SES...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
- This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...